Paul D'Angio
Director/Board Member presso NEXIMMUNE, INC.
Patrimonio netto: 6 244 $ in data 31/03/2024
Profilo
Paul D'Angio is an Independent Director at NexImmune, Inc. He was previously a Senior VP & Global Head-Technical Operations at Celgene Corp.
and a Vice President & Head-Development at Edge Therapeutics, Inc. He also served as Vice President & Head-Manufacturing at PDS Biotechnology Corp.
Mr. D'Angio received his undergraduate degree from Duquesne University of The Holy Spirit and his graduate degree from Seton Hall University School of Law.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
NEXIMMUNE, INC.
0.09% | 31/10/2023 | 1 113 ( 0.09% ) | 6 244 $ | 31/03/2024 |
Posizioni attive di Paul D'Angio
| Società | Posizione | Inizio |
|---|---|---|
| NEXIMMUNE, INC. | Director/Board Member | 01/01/2017 |
Precedenti posizioni note di Paul D'Angio
| Società | Posizione | Fine |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Corporate Officer/Principal | 01/06/2020 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Corporate Officer/Principal | 01/03/2019 |
| CELGENE | Corporate Officer/Principal | - |
Formazione di Paul D'Angio
| Duquesne University of The Holy Spirit | Undergraduate Degree |
| Seton Hall University School of Law | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NEXIMMUNE, INC. | Health Technology |
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Health Technology |
- Borsa valori
- Insiders
- Paul D'Angio
